Browse our comprehensive archive of press releases by date.
Select a specific day to access all press releases published on American Business Times.
Press releases published on April 28, 2025
TScan Therapeutics Announces Upcoming Presentation at the American Society of Gene and Cell Therapy 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
WALTHAM, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- TScan Therapeutics, Inc. (Nasdaq: TCRX), a clinical-stage biotechnology company focused on the development of T cell receptor (TCR)-engineered T cell (TCR-T) therapies for the treatment of patients with …
GROUNDBREAKING NON-INVASIVE THERAPY TREATING FIRST RESPONDERS AND VETERANS, SCORES BIG WITH PROFESSIONAL ATHLETES
EIN Presswire
·
April 28, 2025
VECTTOR™ Technology, a groundbreaking non-invasive therapy designed to treat chronic pain and neurological disorders, is scoring big with professional athletes. WIMBERLEY, TX, UNITED STATES, April 28, 2025 /EINPresswire.com/ -- VECTTOR™ Technology, a …
Cellectis présente une approche non virale d’édition du génome et des innovations avec les base editors à l’ASGCT 2025
GlobeNewswire
·
April 28, 2025
NEW YORK, 28 avr. 2025 (GLOBE NEWSWIRE) -- Cellectis (Euronext Growth : ALCLS - NASDAQ : CLLS) (la "Société"), société de biotechnologie de stade clinique, qui utilise sa technologie pionnière d'édition de génome pour développer des thérapies cellulaires …
RBB Bancorp Reports First Quarter 2025 Earnings
GlobeNewswire
·
April 28, 2025
LOS ANGELES, April 28, 2025 (GLOBE NEWSWIRE) -- RBB Bancorp (NASDAQ:RBB) and its subsidiaries, Royal Business Bank (the “Bank”) and RBB Asset Management Company (“RAM”), collectively referred to herein as the “Company,” announced financial results for the …
iTeos Reports First Quarter 2025 Financial Results and Provides Business Updates
GlobeNewswire
·
April 28, 2025
- Topline interim dataset from GALAXIES Lung-201 with >240 patients anticipated in 2Q25 - Interim datasets from GALAXIES H…
CAMP4 to Present New Preclinical Data from its Urea Cycle Disorders and SYNGAP1-Related Disorders Programs at the 28th American Society of Gene and Cell Therapy Annual Meeting
GlobeNewswire
·
April 28, 2025
Preclinical data to showcase the potential of regRNA-targeting to increase protein levels in a clinically meaningful way by upregulating gene expression Interim safety data including patient demographic data from all SAD cohorts of the first-in-human Phase …
Cellectis Presents Non-Viral Gene Editing and Base Editing Innovation at the ASGCT Annual Meeting
GlobeNewswire
·
April 28, 2025
NEW YORK, April 28, 2025 (GLOBE NEWSWIRE) -- Cellectis (the “Company”) (Euronext Growth: ALCLS - NASDAQ: CLLS), a clinical-stage biotechnology company using its pioneering gene-editing platform to develop life-saving cell and gene therapies, today unveils …
Orchestra BioMed to Participate in Upcoming Institutional Investor Conferences
GlobeNewswire
·
April 28, 2025
NEW HOPE, Pa., April 28, 2025 (GLOBE NEWSWIRE) -- Orchestra BioMed Holdings, Inc. (Nasdaq: OBIO, “Orchestra BioMed” or the “Company”), a biomedical company accelerating high-impact technologies to patients through risk-reward sharing partnerships, today …
Century Therapeutics Announces Two Upcoming Presentations at the ASGCT 28th Annual Meeting
GlobeNewswire
·
April 28, 2025
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Century Therapeutics, Inc. (‘Century’, NASDAQ: IPSC), an innovative biotechnology company developing induced pluripotent stem cell (iPSC)-derived cell therapies in autoimmune disease and cancer, today …
Terra Balcanica annonce un placement fondé sur la dispense pour financement de l’émetteur coté
GlobeNewswire
·
April 28, 2025
NE PAS DIFFUSER AUX ÉTATS-UNIS OU PAR L’INTERMÉDIAIRE DES SERVICES D’INFORMATION DES ÉTATS-UNIS Vancouver, Colombie-Britannique, 28 avr. 2025 (GLOBE NEWSWIRE) -- Terra Balcanica Resources Corp. (« Terra » ou la « Société ») (CSE : TERA; FRA : UB1) a le …
Piedmont Office Realty Trust, Inc. Releases First Quarter 2025 Results
GlobeNewswire
·
April 28, 2025
Atlanta, April 28, 2025 (GLOBE NEWSWIRE) -- Piedmont Office Realty Trust, Inc (NYSE: PDM) has released its financial and operational results for the first quarter of 2025. Please visit the Investor Relations section of Piedmont's website at https:// …
NXP Semiconductors Reports First Quarter 2025 Results, Announces Management Transition
GlobeNewswire
·
April 28, 2025
EINDHOVEN, The Netherlands, April 28, 2025 (GLOBE NEWSWIRE) -- NXP Semiconductors N.V. (NASDAQ: NXPI) today reported financial results for the first quarter, which ended March 30, 2025. “NXP delivered quarterly revenue of $2.84 billion, in-line with the …
Notice to Long-Term Shareholders of Integra Lifesciences Holdings Corporation (NASDAQ: IART); Methode Electronics, Inc. (NYSE: MEI); Monolithic Power Systems, Inc. (NASDAQ: MPWR); and Virtu Financial Inc. (NASDAQ: VIRT): Grabar Law Office Investigates…
GlobeNewswire
·
April 28, 2025
PHILADELPHIA, April 28, 2025 (GLOBE NEWSWIRE) -- Integra LifeSciences Holdings Corp. (NASDAQ: IART): Current Integra LifeSciences Holdings Corp. (NASDAQ: IART) shareholders who have held the stock since on or before March 11, 2019, can seek corporate …
Relay Therapeutics to Announce First Quarter 2025 Financial Results and Corporate Highlights on May 5, 2025
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Relay Therapeutics, Inc. (Nasdaq: RLAY), a clinical-stage precision medicine company transforming the drug discovery process by combining leading-edge computational and experimental technologies, will …
EZCORP Reports Second Quarter Fiscal 2025 Results
GlobeNewswire
·
April 28, 2025
AUSTIN, Texas, April 28, 2025 (GLOBE NEWSWIRE) -- EZCORP, Inc. (NASDAQ: EZPW), a leading provider of pawn transactions in the United States and Latin America, today announced results for its second quarter ended March 31, 2025. Unless otherwise noted, all …
Foghorn Therapeutics Presents New Preclinical Data on Selective SMARCA2 Inhibitor FHD-909 and Selective CBP and Selective EP300 Degrader Programs and Provides Pipeline Update
GlobeNewswire
·
April 28, 2025
- FHD-909 (LY4050784) advancing in Phase 1 trial in SMARCA4 (BRG1) mutated cancers, with non-small cell lung cancer (NSCLC) as the primary target population - Preclinical synergistic anti-tumor activity of FHD-909 in combination with pembrolizumab and KRAS …
Financial Institutions, Inc. Announces First Quarter 2025 Results
GlobeNewswire
·
April 28, 2025
WARSAW, N.Y., April 28, 2025 (GLOBE NEWSWIRE) -- Financial Institutions, Inc. (NASDAQ: FISI) (the "Company," "we" or "us"), parent company of Five Star Bank (the "Bank") and Courier Capital, LLC ("Courier Capital"), today reported financial and operational …
Tempest Presents New Amezalpat MOA Data Reinforcing Its Potential as Novel Cancer Treatment at the 2025 AACR Annual Meeting
GlobeNewswire
·
April 28, 2025
BRISBANE, Calif., April 28, 2025 (GLOBE NEWSWIRE) -- Tempest Therapeutics, Inc. (Nasdaq: TPST), a clinical-stage biotechnology company developing first-in-classi targeted and immune-mediated therapeutics to fight cancer, today announced that a presentation …
Spero Therapeutics Appoints Esther Rajavelu as President and Chief Executive Officer
GlobeNewswire
·
April 28, 2025
CAMBRIDGE, Mass., April 28, 2025 (GLOBE NEWSWIRE) -- Spero Therapeutics, Inc. (Nasdaq: SPRO), a clinical-stage biopharmaceutical company, focused on identifying and developing novel treatments for rare diseases and multi-drug resistant (MDR) bacterial …
Woodward Reports Second Quarter Fiscal Year 2025 Results
GlobeNewswire
·
April 28, 2025
~Results in Line with Expectations, on Track to Deliver Full-Year Guidance~ FORT COLLINS, Colo., April 28, 2025 (GLOBE NEWSWIRE) -- Woodward, Inc. (NASDAQ: WWD) today reported financial results for its second quarter of fiscal year 2025. All amounts are …